Skip to main content
Assets
AstraZeneca logo
AZN.LSE
AstraZeneca
Health Care · Pharmaceuticals

British-Swedish multinational pharmaceutical and biotechnology company developing treatments for cancer, cardiovascular, and respiratory diseases.

HQ: United KingdomListed: United Kingdom

Historical AI Forecasts

Audit every published iPulse AI forecast batch and immutable historical research document for AstraZeneca.

Historical AI Forecasts

AstraZeneca plc (AZN.LSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 11 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 11 April 2026Deep analysis 11 April 2026

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
Elon Musk AI advisor icon

Elon Musk AI

The Visionary FrameworkAI Researcher

Model rating

Strong Buy

5-Year Return Est.

+72.7%

Includes 0.02% annual net dividend contribution

1. Investment Thesis — Base Case

AstraZeneca is positioned as a rapidly transitioning into a Paradigm Shifter, leveraging massive legacy cash flows to acquire the absolute frontier of bio-engineering. The base case forecast assumes an initial defensive rally driven by the Hormuz macro shock, followed by compounding structural growth as their radioconjugate and cell therapy acquisitions scale into production. This is the optimal arrangement of capital and biology, escaping the dead weight of traditional pharma.

  • The market drastically underprices the Fusion and Gracell acquisitions; this is a monopoly on next-gen oncology delivery.
  • Enhertu's continued S-curve acceleration in 1st-line breast cancer will print the cash necessary to fund the actinium without diluting equity.
  • Frictions like will drag on the legacy portfolio, but high-margin precision medicine revenues will mathematically outpace the decay.
  • Oral data will provide intermittent upside volatility, acting as a free call option on the obesity .
  • AZN will compound steadily, absorbing from legacy chemo purveyors unable to innovate. This is not a subsidized fantasy; the are highly profitable and the is ruthless. AZN is buying the future of human longevity at a structural discount.

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in GBX.5.2K10.94K16.69K22.44K28.19KApr 2021Oct 2023Apr 2026Oct 2028Apr 2031Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in GBX.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (GBX)
Observed price2021-04-067,111
Observed price2021-04-227,592
Observed price2021-05-047,629
Observed price2021-05-248,150
Observed price2021-06-017,955
Observed price2021-06-258,478
Observed price2021-07-038,765
Observed price2021-07-238,417
Observed price2021-08-088,232
Observed price2021-08-208,708
Observed price2021-08-248,589
Observed price2021-09-178,063
Observed price2021-09-258,618
Observed price2021-10-119,003
Observed price2021-10-198,739
Observed price2021-11-049,443
Observed price2021-11-168,602
Observed price2021-12-108,193
Observed price2021-12-148,228
Observed price2021-12-308,673
Observed price2022-01-198,785
Observed price2022-02-048,356
Observed price2022-02-088,356
Observed price2022-02-289,167
Observed price2022-03-088,886
Observed price2022-04-0110,135
Observed price2022-04-0510,302
Observed price2022-04-0910,824
Observed price2022-05-0310,684
Observed price2022-05-1110,026
Observed price2022-06-169,760
Observed price2022-06-2410,776
Observed price2022-07-1011,104
Observed price2022-07-2210,766
Observed price2022-08-1110,506
Observed price2022-08-1911,250
Observed price2022-08-2711,241
Observed price2022-09-1610,119
Observed price2022-09-2810,076
Observed price2022-10-149,818
Observed price2022-10-229,719
Observed price2022-11-0310,682
Observed price2022-11-1510,800
Observed price2022-12-0911,354
Observed price2022-12-1711,234
Observed price2023-01-0611,717
Observed price2023-01-1011,685
Observed price2023-02-0310,333
Observed price2023-02-0710,666
Observed price2023-02-1911,496
Observed price2023-03-1110,695
Observed price2023-03-3111,192
Observed price2023-04-0411,432
Observed price2023-04-2412,267
Observed price2023-05-2212,028
Observed price2023-05-2611,613
Observed price2023-06-0711,754
Observed price2023-06-2311,422
Observed price2023-06-2711,190
Observed price2023-07-0910,096
Observed price2023-08-1011,162
Observed price2023-08-1810,658
Observed price2023-09-0310,683
Observed price2023-09-1510,793
Observed price2023-09-1910,839
Observed price2023-09-2711,085
Observed price2023-10-1710,792
Observed price2023-11-0610,240
Observed price2023-11-1810,243
Observed price2023-11-2610,026
Observed price2023-12-1610,226
Observed price2024-01-0510,758
Observed price2024-01-0910,902
Observed price2024-02-0210,360
Observed price2024-02-0610,534
Observed price2024-02-109,662
Observed price2024-03-0510,112
Observed price2024-03-2910,696
Observed price2024-04-0210,604
Observed price2024-04-2611,988
Observed price2024-04-3012,062
Observed price2024-05-2412,329
Observed price2024-05-2812,028
Observed price2024-06-0512,516
Observed price2024-06-2512,550
Observed price2024-07-0712,000
Observed price2024-07-2312,190
Observed price2024-08-1613,046
Observed price2024-09-0113,276
Observed price2024-09-1312,042
Observed price2024-09-1711,936
Observed price2024-09-2911,621
Observed price2024-10-1511,980
Observed price2024-11-089,790
Observed price2024-11-169,990
Observed price2024-12-0210,746
Observed price2024-12-1010,620
Observed price2024-12-1810,375
Observed price2025-01-1510,648
Observed price2025-01-3111,344
Observed price2025-02-0411,030
Observed price2025-02-2811,968
Observed price2025-03-0412,064
Observed price2025-03-2811,416
Observed price2025-04-0111,366
Observed price2025-04-099,667
Observed price2025-05-0310,645
Observed price2025-05-1510,176
Observed price2025-06-1211,030
Observed price2025-06-2010,392
Observed price2025-06-2810,132
Observed price2025-07-1410,662
Observed price2025-07-2210,352
Observed price2025-08-1511,592
Observed price2025-08-1911,782
Observed price2025-09-0412,150
Observed price2025-09-2811,055
Observed price2025-10-1012,886
Observed price2025-10-2212,485
Observed price2025-11-0712,907
Observed price2025-11-1113,322
Observed price2025-11-2714,061
Observed price2025-12-1313,460
Observed price2025-12-2913,737
Observed price2026-01-1414,346
Observed price2026-01-2213,560
Observed price2026-02-0313,816
Observed price2026-02-2715,542
Observed price2026-03-0314,932
Observed price2026-03-2313,742
Observed price2026-04-0415,283
Observed price2026-04-2413,956
Observed price2026-05-0613,322
Observed price2026-05-2213,997
Observed price2026-05-2613,960
Observed price2026-06-1513,200
Observed price2026-07-0514,219
Observed price2026-07-1712,594
Observed price2026-07-2913,134
Observed price2026-08-1411,460
Observed price2026-08-2612,234
Observed price2026-09-1111,708
Observed price2026-09-1512,116
Observed price2026-09-1812,500
Published advisor forecast2026-04-1015,230
Published advisor forecast2026-07-1016,144
Published advisor forecast2026-10-1016,790
Published advisor forecast2027-01-1016,454
Published advisor forecast2027-04-1017,276
Published advisor forecast2027-07-1017,968
Published advisor forecast2027-10-1018,507
Published advisor forecast2028-01-1018,877
Published advisor forecast2028-04-1018,122
Published advisor forecast2028-07-1019,028
Published advisor forecast2028-10-1019,789
Published advisor forecast2029-01-1020,382
Published advisor forecast2029-04-1020,790
Published advisor forecast2029-07-1020,166
Published advisor forecast2029-10-1021,376
Published advisor forecast2030-01-1022,445
Published advisor forecast2030-04-1023,343
Published advisor forecast2030-07-1024,043
Published advisor forecast2030-10-1024,524
Published advisor forecast2031-01-1025,505
Published advisor forecast2031-04-1026,270

2. Scenarios & Signals

Bull case

If AZN's oral perfectly threads the safety needle and their radioconjugate solves the actinium bottleneck, this stock goes fully parabolic. This is not a dream; it is a calculated probability.

  • Oral completely disrupts the duopoly with a vastly cheaper, cold-chain-free manufacturing profile.
  • In-vivo CRISPR platforms deliver outright functional cures for solid tumors.
  • miraculously spares their Chinese R&D infrastructure.
  • completely abandons cyclical tech and apes exclusively into defensive biotech platforms. In this scenario, the combination of obesity capture and nuclear medicine monopoly pushes the valuation to staggering new heights.

Bear case

If the physics of scale betray them, AZN becomes a bloated cash incinerator. This happens if the integration of their acquired platforms hits hard thermodynamic or regulatory limits.

  • The actinium completely fails, rendering the Fusion acquisition a stranded asset.
  • US-China geopolitical hard-fencing forces a distressed divestiture of Gracell, destroying their cell therapy runway.
  • expand aggressively into complex biologics, capping upside.
  • Legacy patent cliffs accelerate faster than expected, throwing the company into a cash flow crunch. Under these conditions, AZN bleeds out market cap as legacy S-curves die before new ones can replace them.

Current crowd narrative

The noisy market is pricing AZN like a solid boomer defensive play riding the Enhertu wave while desperately trying to catch Novo Nordisk and Eli Lilly in the obesity hype cycle. The consensus treats it as a safe place to hide during the Iran War and macro volatility, anchored entirely by trailing P/E ratios and dividends. They see a pharmaceutical company optimizing chemistry, completely missing the platform shift occurring beneath the surface.

Alpha-gap assessment

The here is that AZN is actively monopolizing the atomic layer of precision oncology. By acquiring Fusion's radioconjugates and Gracell's CAR-T platforms, they are not just creating new drugs; they are building an impenetrable bio-engineering infrastructure. Wall Street analysts are staring at cash flows and missing the fact that AZN is weaponizing nuclear isotopes and reprogramming T-cells to eradicate the fundamental physics of solid tumors. The is massive because the street prices legacy chemistry, but AZN is building first-principles physics.

Convergence catalyst

The catalyst that closes this will be the late 2026 and 2027 Phase II/III clinical readouts for FPI-2265 and GC012F. When the efficacy data drops and shows complete response rates that physically humiliate traditional chemotherapy, the market will abruptly reprice AZN from a pharma dinosaur to a next-gen bio-platform.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus